Nassar M, Baraka B, Talal AH. Innovative approaches in predicting outcomes for rectal neuroendocrine tumors. World J Gastroenterol 2025; 31(6): 100517 [PMID: PMC11752703 DOI: 10.3748/wjg.v31.i6.100517]
Corresponding Author of This Article
Mahmoud Nassar, MD, MSc, PhD, Academic Editor, Staff Physician, Department of Internal Medicine, Jacobs School of Medicine and Biomedical Sciences, University of Buffalo, 705 Maple Road, Buffalo, NY 14221, United States. dr.nassar@aucegypt.edu
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Feb 14, 2025; 31(6): 100517 Published online Feb 14, 2025. doi: 10.3748/wjg.v31.i6.100517
Innovative approaches in predicting outcomes for rectal neuroendocrine tumors
Mahmoud Nassar, Bahaaeldin Baraka, Andrew H Talal
Mahmoud Nassar, Department of Internal Medicine, Jacobs School of Medicine and Biomedical Sciences, University of Buffalo, Buffalo, NY 14221, United States
Mahmoud Nassar, Department of Research, American Society for Inclusion, Diversity, and Equity in Healthcare, Lewes, DE 19958, United States
Bahaaeldin Baraka, Medical Oncologist, Oncology, Nottingham University Hospitals, City Hospital, Nottingham NG5 1PB, United Kingdom
Andrew H Talal, Department of Medicine, University at Buffalo, State University of New York, Buffalo, NY 14203, United States
Author contributions: Nassar M, Baraka B, and Talal AH contributed equally to the writing and editing of the manuscript; Talal AH additionally reviewed the article for critical content.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article. Talal AH reports grant and research support from Gilead, Abbott Laboratories, Novo Nordisk, AstraZeneca, and Salix. Additionally, Talal AH serves on committees or as an advisor for Gilead, AbbVie, and Novo Nordisk.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Mahmoud Nassar, MD, MSc, PhD, Academic Editor, Staff Physician, Department of Internal Medicine, Jacobs School of Medicine and Biomedical Sciences, University of Buffalo, 705 Maple Road, Buffalo, NY 14221, United States. dr.nassar@aucegypt.edu
Received: August 18, 2024 Revised: November 5, 2024 Accepted: December 9, 2024 Published online: February 14, 2025 Processing time: 144 Days and 15.1 Hours
Abstract
Rectal neuroendocrine neoplasms pose significant challenges due to their varied presentations and prognoses. Traditional prognostic models, while useful, often fall short of accurately predicting clinical outcomes for these patients. This article discusses the development and implications of a novel prognostic tool, the GATIS score, which aims to enhance predictive accuracy and guide treatment strategies more effectively than current methods. Utilizing data from a large cohort and employing sophisticated statistical models, the GATIS score integrates clinical and pathological markers to provide a nuanced assessment of prognosis. We evaluate the potential of this score to transform clinical decision-making processes, its integration into current medical practices, and future directions for its development. The integration of genetic markers and other biomarkers could further refine its predictive power, highlighting the ongoing need for innovation in the management of rectal neuroendocrine neoplasms.
Core Tip: The GATIS score is a new prognostic tool for rectal neuroendocrine neoplasms, enhancing accuracy by combining clinical and pathological factors. Its use in clinical decision-making could transform treatment approaches by tailoring them to patient risk levels, guiding management, and informing surveillance to detect early recurrence. This tool also aids in selecting clinical trial candidates, which could promote research and the development of new therapies.
